4D Molecular Therapeutics (FDMT) said Friday that it will focus on two product candidates: 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.

The company said the two candidates have the strongest clinical proof of concept within its product pipeline.

4D said it is on track to begin late-stage trials for wet AMD in Q1 and Q3 respectively, with primary endpoint 52-week topline data expected in H2 2027.

Shares of the biotech firm were up 5.7% in recent premarket activity.

Price: 6.16, Change: +0.32, Percent Change: +5.65